Pharma & Healthcare
Global Anti-VEGT Drugs Market Research Report 2025
- Jun 06, 25
- ID: 289267
- Pages: 93
- Figures: 89
- Views: 24
The global market for Anti-VEGT Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Anti-VEGF (Vascular Endothelial Growth Factor) drugs are a class of medications used to treat various eye conditions, particularly those affecting the retina and blood vessels at the back of the eye. VEGF is a protein that promotes the growth of new blood vessels. In certain eye diseases, excessive VEGF can contribute to abnormal blood vessel growth and leakage, causing vision problems or loss.
Anti-VEGF drugs work by inhibiting or blocking the activity of VEGF, thus helping to reduce the growth of abnormal blood vessels and fluid leakage within the eye. These drugs are administered directly into the eye using injections.
North American market for Anti-VEGT Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Anti-VEGT Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Anti-VEGT Drugs include Genentech (Roche), Regeneron Pharmaceuticals, Novartis, AstraZeneca, Bayer, Abbott, Santen, Pfizer, Sanofi, Bristol-Myers Squibb, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Anti-VEGT Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-VEGT Drugs.
The Anti-VEGT Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Anti-VEGT Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-VEGT Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Genentech (Roche)
Regeneron Pharmaceuticals
Novartis
AstraZeneca
Bayer
Abbott
Santen
Pfizer
Sanofi
Bristol-Myers Squibb
GlaxoSmithKline
Eli Lilly & Company
Chugai Pharma
Kanghong Pharmaceutical
Segment by Type
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
Segment by Application
Oncology
Ophthalmology
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-VEGT Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-VEGT Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Anti-VEGF (Vascular Endothelial Growth Factor) drugs are a class of medications used to treat various eye conditions, particularly those affecting the retina and blood vessels at the back of the eye. VEGF is a protein that promotes the growth of new blood vessels. In certain eye diseases, excessive VEGF can contribute to abnormal blood vessel growth and leakage, causing vision problems or loss.
Anti-VEGF drugs work by inhibiting or blocking the activity of VEGF, thus helping to reduce the growth of abnormal blood vessels and fluid leakage within the eye. These drugs are administered directly into the eye using injections.
North American market for Anti-VEGT Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Anti-VEGT Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Anti-VEGT Drugs include Genentech (Roche), Regeneron Pharmaceuticals, Novartis, AstraZeneca, Bayer, Abbott, Santen, Pfizer, Sanofi, Bristol-Myers Squibb, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Anti-VEGT Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-VEGT Drugs.
The Anti-VEGT Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Anti-VEGT Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-VEGT Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Genentech (Roche)
Regeneron Pharmaceuticals
Novartis
AstraZeneca
Bayer
Abbott
Santen
Pfizer
Sanofi
Bristol-Myers Squibb
GlaxoSmithKline
Eli Lilly & Company
Chugai Pharma
Kanghong Pharmaceutical
Segment by Type
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
Segment by Application
Oncology
Ophthalmology
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-VEGT Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-VEGT Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Anti-VEGT Drugs Market Overview
1.1 Product Definition
1.2 Anti-VEGT Drugs by Type
1.2.1 Global Anti-VEGT Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Tyrosine Kinase Inhibitors
1.2.3 Monoclonal Antibodies
1.2.4 Others
1.3 Anti-VEGT Drugs by Application
1.3.1 Global Anti-VEGT Drugs Market Value by Application (2024 VS 2031)
1.3.2 Oncology
1.3.3 Ophthalmology
1.3.4 Others
1.4 Global Anti-VEGT Drugs Market Size Estimates and Forecasts
1.4.1 Global Anti-VEGT Drugs Revenue 2020-2031
1.4.2 Global Anti-VEGT Drugs Sales 2020-2031
1.4.3 Global Anti-VEGT Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Anti-VEGT Drugs Market Competition by Manufacturers
2.1 Global Anti-VEGT Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Anti-VEGT Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Anti-VEGT Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Anti-VEGT Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Anti-VEGT Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-VEGT Drugs, Product Type & Application
2.7 Global Key Manufacturers of Anti-VEGT Drugs, Date of Enter into This Industry
2.8 Global Anti-VEGT Drugs Market Competitive Situation and Trends
2.8.1 Global Anti-VEGT Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Anti-VEGT Drugs Players Market Share by Revenue
2.8.3 Global Anti-VEGT Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Anti-VEGT Drugs Market Scenario by Region
3.1 Global Anti-VEGT Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Anti-VEGT Drugs Sales by Region: 2020-2031
3.2.1 Global Anti-VEGT Drugs Sales by Region: 2020-2025
3.2.2 Global Anti-VEGT Drugs Sales by Region: 2026-2031
3.3 Global Anti-VEGT Drugs Revenue by Region: 2020-2031
3.3.1 Global Anti-VEGT Drugs Revenue by Region: 2020-2025
3.3.2 Global Anti-VEGT Drugs Revenue by Region: 2026-2031
3.4 North America Anti-VEGT Drugs Market Facts & Figures by Country
3.4.1 North America Anti-VEGT Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Anti-VEGT Drugs Sales by Country (2020-2031)
3.4.3 North America Anti-VEGT Drugs Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Anti-VEGT Drugs Market Facts & Figures by Country
3.5.1 Europe Anti-VEGT Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Anti-VEGT Drugs Sales by Country (2020-2031)
3.5.3 Europe Anti-VEGT Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-VEGT Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Anti-VEGT Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Anti-VEGT Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Anti-VEGT Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Anti-VEGT Drugs Market Facts & Figures by Country
3.7.1 Latin America Anti-VEGT Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Anti-VEGT Drugs Sales by Country (2020-2031)
3.7.3 Latin America Anti-VEGT Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Anti-VEGT Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-VEGT Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Anti-VEGT Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Anti-VEGT Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-VEGT Drugs Sales by Type (2020-2031)
4.1.1 Global Anti-VEGT Drugs Sales by Type (2020-2025)
4.1.2 Global Anti-VEGT Drugs Sales by Type (2026-2031)
4.1.3 Global Anti-VEGT Drugs Sales Market Share by Type (2020-2031)
4.2 Global Anti-VEGT Drugs Revenue by Type (2020-2031)
4.2.1 Global Anti-VEGT Drugs Revenue by Type (2020-2025)
4.2.2 Global Anti-VEGT Drugs Revenue by Type (2026-2031)
4.2.3 Global Anti-VEGT Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Anti-VEGT Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Anti-VEGT Drugs Sales by Application (2020-2031)
5.1.1 Global Anti-VEGT Drugs Sales by Application (2020-2025)
5.1.2 Global Anti-VEGT Drugs Sales by Application (2026-2031)
5.1.3 Global Anti-VEGT Drugs Sales Market Share by Application (2020-2031)
5.2 Global Anti-VEGT Drugs Revenue by Application (2020-2031)
5.2.1 Global Anti-VEGT Drugs Revenue by Application (2020-2025)
5.2.2 Global Anti-VEGT Drugs Revenue by Application (2026-2031)
5.2.3 Global Anti-VEGT Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Anti-VEGT Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Genentech (Roche)
6.1.1 Genentech (Roche) Company Information
6.1.2 Genentech (Roche) Description and Business Overview
6.1.3 Genentech (Roche) Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Genentech (Roche) Anti-VEGT Drugs Product Portfolio
6.1.5 Genentech (Roche) Recent Developments/Updates
6.2 Regeneron Pharmaceuticals
6.2.1 Regeneron Pharmaceuticals Company Information
6.2.2 Regeneron Pharmaceuticals Description and Business Overview
6.2.3 Regeneron Pharmaceuticals Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Regeneron Pharmaceuticals Anti-VEGT Drugs Product Portfolio
6.2.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Company Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Novartis Anti-VEGT Drugs Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 AstraZeneca
6.4.1 AstraZeneca Company Information
6.4.2 AstraZeneca Description and Business Overview
6.4.3 AstraZeneca Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 AstraZeneca Anti-VEGT Drugs Product Portfolio
6.4.5 AstraZeneca Recent Developments/Updates
6.5 Bayer
6.5.1 Bayer Company Information
6.5.2 Bayer Description and Business Overview
6.5.3 Bayer Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Bayer Anti-VEGT Drugs Product Portfolio
6.5.5 Bayer Recent Developments/Updates
6.6 Abbott
6.6.1 Abbott Company Information
6.6.2 Abbott Description and Business Overview
6.6.3 Abbott Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Abbott Anti-VEGT Drugs Product Portfolio
6.6.5 Abbott Recent Developments/Updates
6.7 Santen
6.7.1 Santen Company Information
6.7.2 Santen Description and Business Overview
6.7.3 Santen Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Santen Anti-VEGT Drugs Product Portfolio
6.7.5 Santen Recent Developments/Updates
6.8 Pfizer
6.8.1 Pfizer Company Information
6.8.2 Pfizer Description and Business Overview
6.8.3 Pfizer Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Pfizer Anti-VEGT Drugs Product Portfolio
6.8.5 Pfizer Recent Developments/Updates
6.9 Sanofi
6.9.1 Sanofi Company Information
6.9.2 Sanofi Description and Business Overview
6.9.3 Sanofi Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Sanofi Anti-VEGT Drugs Product Portfolio
6.9.5 Sanofi Recent Developments/Updates
6.10 Bristol-Myers Squibb
6.10.1 Bristol-Myers Squibb Company Information
6.10.2 Bristol-Myers Squibb Description and Business Overview
6.10.3 Bristol-Myers Squibb Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Bristol-Myers Squibb Anti-VEGT Drugs Product Portfolio
6.10.5 Bristol-Myers Squibb Recent Developments/Updates
6.11 GlaxoSmithKline
6.11.1 GlaxoSmithKline Company Information
6.11.2 GlaxoSmithKline Description and Business Overview
6.11.3 GlaxoSmithKline Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.11.4 GlaxoSmithKline Anti-VEGT Drugs Product Portfolio
6.11.5 GlaxoSmithKline Recent Developments/Updates
6.12 Eli Lilly & Company
6.12.1 Eli Lilly & Company Company Information
6.12.2 Eli Lilly & Company Description and Business Overview
6.12.3 Eli Lilly & Company Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Eli Lilly & Company Anti-VEGT Drugs Product Portfolio
6.12.5 Eli Lilly & Company Recent Developments/Updates
6.13 Chugai Pharma
6.13.1 Chugai Pharma Company Information
6.13.2 Chugai Pharma Description and Business Overview
6.13.3 Chugai Pharma Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Chugai Pharma Anti-VEGT Drugs Product Portfolio
6.13.5 Chugai Pharma Recent Developments/Updates
6.14 Kanghong Pharmaceutical
6.14.1 Kanghong Pharmaceutical Company Information
6.14.2 Kanghong Pharmaceutical Description and Business Overview
6.14.3 Kanghong Pharmaceutical Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Kanghong Pharmaceutical Anti-VEGT Drugs Product Portfolio
6.14.5 Kanghong Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-VEGT Drugs Industry Chain Analysis
7.2 Anti-VEGT Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-VEGT Drugs Production Mode & Process Analysis
7.4 Anti-VEGT Drugs Sales and Marketing
7.4.1 Anti-VEGT Drugs Sales Channels
7.4.2 Anti-VEGT Drugs Distributors
7.5 Anti-VEGT Drugs Customer Analysis
8 Anti-VEGT Drugs Market Dynamics
8.1 Anti-VEGT Drugs Industry Trends
8.2 Anti-VEGT Drugs Market Drivers
8.3 Anti-VEGT Drugs Market Challenges
8.4 Anti-VEGT Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Anti-VEGT Drugs by Type
1.2.1 Global Anti-VEGT Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Tyrosine Kinase Inhibitors
1.2.3 Monoclonal Antibodies
1.2.4 Others
1.3 Anti-VEGT Drugs by Application
1.3.1 Global Anti-VEGT Drugs Market Value by Application (2024 VS 2031)
1.3.2 Oncology
1.3.3 Ophthalmology
1.3.4 Others
1.4 Global Anti-VEGT Drugs Market Size Estimates and Forecasts
1.4.1 Global Anti-VEGT Drugs Revenue 2020-2031
1.4.2 Global Anti-VEGT Drugs Sales 2020-2031
1.4.3 Global Anti-VEGT Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Anti-VEGT Drugs Market Competition by Manufacturers
2.1 Global Anti-VEGT Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Anti-VEGT Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Anti-VEGT Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Anti-VEGT Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Anti-VEGT Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-VEGT Drugs, Product Type & Application
2.7 Global Key Manufacturers of Anti-VEGT Drugs, Date of Enter into This Industry
2.8 Global Anti-VEGT Drugs Market Competitive Situation and Trends
2.8.1 Global Anti-VEGT Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Anti-VEGT Drugs Players Market Share by Revenue
2.8.3 Global Anti-VEGT Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Anti-VEGT Drugs Market Scenario by Region
3.1 Global Anti-VEGT Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Anti-VEGT Drugs Sales by Region: 2020-2031
3.2.1 Global Anti-VEGT Drugs Sales by Region: 2020-2025
3.2.2 Global Anti-VEGT Drugs Sales by Region: 2026-2031
3.3 Global Anti-VEGT Drugs Revenue by Region: 2020-2031
3.3.1 Global Anti-VEGT Drugs Revenue by Region: 2020-2025
3.3.2 Global Anti-VEGT Drugs Revenue by Region: 2026-2031
3.4 North America Anti-VEGT Drugs Market Facts & Figures by Country
3.4.1 North America Anti-VEGT Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Anti-VEGT Drugs Sales by Country (2020-2031)
3.4.3 North America Anti-VEGT Drugs Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Anti-VEGT Drugs Market Facts & Figures by Country
3.5.1 Europe Anti-VEGT Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Anti-VEGT Drugs Sales by Country (2020-2031)
3.5.3 Europe Anti-VEGT Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-VEGT Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Anti-VEGT Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Anti-VEGT Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Anti-VEGT Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Anti-VEGT Drugs Market Facts & Figures by Country
3.7.1 Latin America Anti-VEGT Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Anti-VEGT Drugs Sales by Country (2020-2031)
3.7.3 Latin America Anti-VEGT Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Anti-VEGT Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-VEGT Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Anti-VEGT Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Anti-VEGT Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-VEGT Drugs Sales by Type (2020-2031)
4.1.1 Global Anti-VEGT Drugs Sales by Type (2020-2025)
4.1.2 Global Anti-VEGT Drugs Sales by Type (2026-2031)
4.1.3 Global Anti-VEGT Drugs Sales Market Share by Type (2020-2031)
4.2 Global Anti-VEGT Drugs Revenue by Type (2020-2031)
4.2.1 Global Anti-VEGT Drugs Revenue by Type (2020-2025)
4.2.2 Global Anti-VEGT Drugs Revenue by Type (2026-2031)
4.2.3 Global Anti-VEGT Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Anti-VEGT Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Anti-VEGT Drugs Sales by Application (2020-2031)
5.1.1 Global Anti-VEGT Drugs Sales by Application (2020-2025)
5.1.2 Global Anti-VEGT Drugs Sales by Application (2026-2031)
5.1.3 Global Anti-VEGT Drugs Sales Market Share by Application (2020-2031)
5.2 Global Anti-VEGT Drugs Revenue by Application (2020-2031)
5.2.1 Global Anti-VEGT Drugs Revenue by Application (2020-2025)
5.2.2 Global Anti-VEGT Drugs Revenue by Application (2026-2031)
5.2.3 Global Anti-VEGT Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Anti-VEGT Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Genentech (Roche)
6.1.1 Genentech (Roche) Company Information
6.1.2 Genentech (Roche) Description and Business Overview
6.1.3 Genentech (Roche) Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Genentech (Roche) Anti-VEGT Drugs Product Portfolio
6.1.5 Genentech (Roche) Recent Developments/Updates
6.2 Regeneron Pharmaceuticals
6.2.1 Regeneron Pharmaceuticals Company Information
6.2.2 Regeneron Pharmaceuticals Description and Business Overview
6.2.3 Regeneron Pharmaceuticals Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Regeneron Pharmaceuticals Anti-VEGT Drugs Product Portfolio
6.2.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Company Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Novartis Anti-VEGT Drugs Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 AstraZeneca
6.4.1 AstraZeneca Company Information
6.4.2 AstraZeneca Description and Business Overview
6.4.3 AstraZeneca Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 AstraZeneca Anti-VEGT Drugs Product Portfolio
6.4.5 AstraZeneca Recent Developments/Updates
6.5 Bayer
6.5.1 Bayer Company Information
6.5.2 Bayer Description and Business Overview
6.5.3 Bayer Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Bayer Anti-VEGT Drugs Product Portfolio
6.5.5 Bayer Recent Developments/Updates
6.6 Abbott
6.6.1 Abbott Company Information
6.6.2 Abbott Description and Business Overview
6.6.3 Abbott Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Abbott Anti-VEGT Drugs Product Portfolio
6.6.5 Abbott Recent Developments/Updates
6.7 Santen
6.7.1 Santen Company Information
6.7.2 Santen Description and Business Overview
6.7.3 Santen Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Santen Anti-VEGT Drugs Product Portfolio
6.7.5 Santen Recent Developments/Updates
6.8 Pfizer
6.8.1 Pfizer Company Information
6.8.2 Pfizer Description and Business Overview
6.8.3 Pfizer Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Pfizer Anti-VEGT Drugs Product Portfolio
6.8.5 Pfizer Recent Developments/Updates
6.9 Sanofi
6.9.1 Sanofi Company Information
6.9.2 Sanofi Description and Business Overview
6.9.3 Sanofi Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Sanofi Anti-VEGT Drugs Product Portfolio
6.9.5 Sanofi Recent Developments/Updates
6.10 Bristol-Myers Squibb
6.10.1 Bristol-Myers Squibb Company Information
6.10.2 Bristol-Myers Squibb Description and Business Overview
6.10.3 Bristol-Myers Squibb Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Bristol-Myers Squibb Anti-VEGT Drugs Product Portfolio
6.10.5 Bristol-Myers Squibb Recent Developments/Updates
6.11 GlaxoSmithKline
6.11.1 GlaxoSmithKline Company Information
6.11.2 GlaxoSmithKline Description and Business Overview
6.11.3 GlaxoSmithKline Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.11.4 GlaxoSmithKline Anti-VEGT Drugs Product Portfolio
6.11.5 GlaxoSmithKline Recent Developments/Updates
6.12 Eli Lilly & Company
6.12.1 Eli Lilly & Company Company Information
6.12.2 Eli Lilly & Company Description and Business Overview
6.12.3 Eli Lilly & Company Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Eli Lilly & Company Anti-VEGT Drugs Product Portfolio
6.12.5 Eli Lilly & Company Recent Developments/Updates
6.13 Chugai Pharma
6.13.1 Chugai Pharma Company Information
6.13.2 Chugai Pharma Description and Business Overview
6.13.3 Chugai Pharma Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Chugai Pharma Anti-VEGT Drugs Product Portfolio
6.13.5 Chugai Pharma Recent Developments/Updates
6.14 Kanghong Pharmaceutical
6.14.1 Kanghong Pharmaceutical Company Information
6.14.2 Kanghong Pharmaceutical Description and Business Overview
6.14.3 Kanghong Pharmaceutical Anti-VEGT Drugs Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Kanghong Pharmaceutical Anti-VEGT Drugs Product Portfolio
6.14.5 Kanghong Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-VEGT Drugs Industry Chain Analysis
7.2 Anti-VEGT Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-VEGT Drugs Production Mode & Process Analysis
7.4 Anti-VEGT Drugs Sales and Marketing
7.4.1 Anti-VEGT Drugs Sales Channels
7.4.2 Anti-VEGT Drugs Distributors
7.5 Anti-VEGT Drugs Customer Analysis
8 Anti-VEGT Drugs Market Dynamics
8.1 Anti-VEGT Drugs Industry Trends
8.2 Anti-VEGT Drugs Market Drivers
8.3 Anti-VEGT Drugs Market Challenges
8.4 Anti-VEGT Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Anti-VEGT Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Anti-VEGT Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Anti-VEGT Drugs Market Competitive Situation by Manufacturers in 2024
Table 4. Global Anti-VEGT Drugs Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Anti-VEGT Drugs Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Anti-VEGT Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Anti-VEGT Drugs Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Anti-VEGT Drugs Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Anti-VEGT Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Anti-VEGT Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Anti-VEGT Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Anti-VEGT Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Anti-VEGT Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGT Drugs as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Anti-VEGT Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Anti-VEGT Drugs Sales by Region (2020-2025) & (K Units)
Table 18. Global Anti-VEGT Drugs Sales Market Share by Region (2020-2025)
Table 19. Global Anti-VEGT Drugs Sales by Region (2026-2031) & (K Units)
Table 20. Global Anti-VEGT Drugs Sales Market Share by Region (2026-2031)
Table 21. Global Anti-VEGT Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Anti-VEGT Drugs Revenue Market Share by Region (2020-2025)
Table 23. Global Anti-VEGT Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Anti-VEGT Drugs Revenue Market Share by Region (2026-2031)
Table 25. North America Anti-VEGT Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Anti-VEGT Drugs Sales by Country (2020-2025) & (K Units)
Table 27. North America Anti-VEGT Drugs Sales by Country (2026-2031) & (K Units)
Table 28. North America Anti-VEGT Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Anti-VEGT Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Anti-VEGT Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Anti-VEGT Drugs Sales by Country (2020-2025) & (K Units)
Table 32. Europe Anti-VEGT Drugs Sales by Country (2026-2031) & (K Units)
Table 33. Europe Anti-VEGT Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Anti-VEGT Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Anti-VEGT Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Anti-VEGT Drugs Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Anti-VEGT Drugs Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Anti-VEGT Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Anti-VEGT Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Anti-VEGT Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Anti-VEGT Drugs Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Anti-VEGT Drugs Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Anti-VEGT Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Anti-VEGT Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Anti-VEGT Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Anti-VEGT Drugs Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Anti-VEGT Drugs Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Anti-VEGT Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Anti-VEGT Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Anti-VEGT Drugs Sales (K Units) by Type (2020-2025)
Table 51. Global Anti-VEGT Drugs Sales (K Units) by Type (2026-2031)
Table 52. Global Anti-VEGT Drugs Sales Market Share by Type (2020-2025)
Table 53. Global Anti-VEGT Drugs Sales Market Share by Type (2026-2031)
Table 54. Global Anti-VEGT Drugs Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Anti-VEGT Drugs Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Anti-VEGT Drugs Revenue Market Share by Type (2020-2025)
Table 57. Global Anti-VEGT Drugs Revenue Market Share by Type (2026-2031)
Table 58. Global Anti-VEGT Drugs Price (US$/Unit) by Type (2020-2025)
Table 59. Global Anti-VEGT Drugs Price (US$/Unit) by Type (2026-2031)
Table 60. Global Anti-VEGT Drugs Sales (K Units) by Application (2020-2025)
Table 61. Global Anti-VEGT Drugs Sales (K Units) by Application (2026-2031)
Table 62. Global Anti-VEGT Drugs Sales Market Share by Application (2020-2025)
Table 63. Global Anti-VEGT Drugs Sales Market Share by Application (2026-2031)
Table 64. Global Anti-VEGT Drugs Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Anti-VEGT Drugs Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Anti-VEGT Drugs Revenue Market Share by Application (2020-2025)
Table 67. Global Anti-VEGT Drugs Revenue Market Share by Application (2026-2031)
Table 68. Global Anti-VEGT Drugs Price (US$/Unit) by Application (2020-2025)
Table 69. Global Anti-VEGT Drugs Price (US$/Unit) by Application (2026-2031)
Table 70. Genentech (Roche) Company Information
Table 71. Genentech (Roche) Description and Business Overview
Table 72. Genentech (Roche) Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Genentech (Roche) Anti-VEGT Drugs Product
Table 74. Genentech (Roche) Recent Developments/Updates
Table 75. Regeneron Pharmaceuticals Company Information
Table 76. Regeneron Pharmaceuticals Description and Business Overview
Table 77. Regeneron Pharmaceuticals Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Regeneron Pharmaceuticals Anti-VEGT Drugs Product
Table 79. Regeneron Pharmaceuticals Recent Developments/Updates
Table 80. Novartis Company Information
Table 81. Novartis Description and Business Overview
Table 82. Novartis Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Novartis Anti-VEGT Drugs Product
Table 84. Novartis Recent Developments/Updates
Table 85. AstraZeneca Company Information
Table 86. AstraZeneca Description and Business Overview
Table 87. AstraZeneca Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. AstraZeneca Anti-VEGT Drugs Product
Table 89. AstraZeneca Recent Developments/Updates
Table 90. Bayer Company Information
Table 91. Bayer Description and Business Overview
Table 92. Bayer Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Bayer Anti-VEGT Drugs Product
Table 94. Bayer Recent Developments/Updates
Table 95. Abbott Company Information
Table 96. Abbott Description and Business Overview
Table 97. Abbott Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Abbott Anti-VEGT Drugs Product
Table 99. Abbott Recent Developments/Updates
Table 100. Santen Company Information
Table 101. Santen Description and Business Overview
Table 102. Santen Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Santen Anti-VEGT Drugs Product
Table 104. Santen Recent Developments/Updates
Table 105. Pfizer Company Information
Table 106. Pfizer Description and Business Overview
Table 107. Pfizer Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Pfizer Anti-VEGT Drugs Product
Table 109. Pfizer Recent Developments/Updates
Table 110. Sanofi Company Information
Table 111. Sanofi Description and Business Overview
Table 112. Sanofi Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Sanofi Anti-VEGT Drugs Product
Table 114. Sanofi Recent Developments/Updates
Table 115. Bristol-Myers Squibb Company Information
Table 116. Bristol-Myers Squibb Description and Business Overview
Table 117. Bristol-Myers Squibb Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Bristol-Myers Squibb Anti-VEGT Drugs Product
Table 119. Bristol-Myers Squibb Recent Developments/Updates
Table 120. GlaxoSmithKline Company Information
Table 121. GlaxoSmithKline Description and Business Overview
Table 122. GlaxoSmithKline Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. GlaxoSmithKline Anti-VEGT Drugs Product
Table 124. GlaxoSmithKline Recent Developments/Updates
Table 125. Eli Lilly & Company Company Information
Table 126. Eli Lilly & Company Description and Business Overview
Table 127. Eli Lilly & Company Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Eli Lilly & Company Anti-VEGT Drugs Product
Table 129. Eli Lilly & Company Recent Developments/Updates
Table 130. Chugai Pharma Company Information
Table 131. Chugai Pharma Description and Business Overview
Table 132. Chugai Pharma Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. Chugai Pharma Anti-VEGT Drugs Product
Table 134. Chugai Pharma Recent Developments/Updates
Table 135. Kanghong Pharmaceutical Company Information
Table 136. Kanghong Pharmaceutical Description and Business Overview
Table 137. Kanghong Pharmaceutical Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Kanghong Pharmaceutical Anti-VEGT Drugs Product
Table 139. Kanghong Pharmaceutical Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Anti-VEGT Drugs Distributors List
Table 143. Anti-VEGT Drugs Customers List
Table 144. Anti-VEGT Drugs Market Trends
Table 145. Anti-VEGT Drugs Market Drivers
Table 146. Anti-VEGT Drugs Market Challenges
Table 147. Anti-VEGT Drugs Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
Table 151. Authors List of This Report
List of Figures
Figure 1. Product Picture of Anti-VEGT Drugs
Figure 2. Global Anti-VEGT Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Anti-VEGT Drugs Market Share by Type: 2024 & 2031
Figure 4. Tyrosine Kinase Inhibitors Product Picture
Figure 5. Monoclonal Antibodies Product Picture
Figure 6. Others Product Picture
Figure 7. Global Anti-VEGT Drugs Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Anti-VEGT Drugs Market Share by Application: 2024 & 2031
Figure 9. Oncology
Figure 10. Ophthalmology
Figure 11. Others
Figure 12. Global Anti-VEGT Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Anti-VEGT Drugs Market Size (2020-2031) & (US$ Million)
Figure 14. Global Anti-VEGT Drugs Sales (2020-2031) & (K Units)
Figure 15. Global Anti-VEGT Drugs Average Price (US$/Unit) & (2020-2031)
Figure 16. Anti-VEGT Drugs Report Years Considered
Figure 17. Anti-VEGT Drugs Sales Share by Manufacturers in 2024
Figure 18. Global Anti-VEGT Drugs Revenue Share by Manufacturers in 2024
Figure 19. Global 5 and 10 Largest Anti-VEGT Drugs Players: Market Share by Revenue in Anti-VEGT Drugs in 2024
Figure 20. Anti-VEGT Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Global Anti-VEGT Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 22. North America Anti-VEGT Drugs Sales Market Share by Country (2020-2031)
Figure 23. North America Anti-VEGT Drugs Revenue Market Share by Country (2020-2031)
Figure 24. United States Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Canada Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Europe Anti-VEGT Drugs Sales Market Share by Country (2020-2031)
Figure 27. Europe Anti-VEGT Drugs Revenue Market Share by Country (2020-2031)
Figure 28. Germany Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. France Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. U.K. Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Italy Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Russia Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Asia Pacific Anti-VEGT Drugs Sales Market Share by Region (2020-2031)
Figure 34. Asia Pacific Anti-VEGT Drugs Revenue Market Share by Region (2020-2031)
Figure 35. China Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Japan Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. South Korea Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. India Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Australia Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. China Taiwan Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Southeast Asia Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Latin America Anti-VEGT Drugs Sales Market Share by Country (2020-2031)
Figure 43. Latin America Anti-VEGT Drugs Revenue Market Share by Country (2020-2031)
Figure 44. Mexico Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Brazil Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Argentina Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Middle East and Africa Anti-VEGT Drugs Sales Market Share by Country (2020-2031)
Figure 48. Middle East and Africa Anti-VEGT Drugs Revenue Market Share by Country (2020-2031)
Figure 49. Turkey Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Saudi Arabia Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. UAE Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Global Sales Market Share of Anti-VEGT Drugs by Type (2020-2031)
Figure 53. Global Revenue Market Share of Anti-VEGT Drugs by Type (2020-2031)
Figure 54. Global Anti-VEGT Drugs Price (US$/Unit) by Type (2020-2031)
Figure 55. Global Sales Market Share of Anti-VEGT Drugs by Application (2020-2031)
Figure 56. Global Revenue Market Share of Anti-VEGT Drugs by Application (2020-2031)
Figure 57. Global Anti-VEGT Drugs Price (US$/Unit) by Application (2020-2031)
Figure 58. Anti-VEGT Drugs Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Table 1. Global Anti-VEGT Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Anti-VEGT Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Anti-VEGT Drugs Market Competitive Situation by Manufacturers in 2024
Table 4. Global Anti-VEGT Drugs Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Anti-VEGT Drugs Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Anti-VEGT Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Anti-VEGT Drugs Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Anti-VEGT Drugs Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Anti-VEGT Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Anti-VEGT Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Anti-VEGT Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Anti-VEGT Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Anti-VEGT Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGT Drugs as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Anti-VEGT Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Anti-VEGT Drugs Sales by Region (2020-2025) & (K Units)
Table 18. Global Anti-VEGT Drugs Sales Market Share by Region (2020-2025)
Table 19. Global Anti-VEGT Drugs Sales by Region (2026-2031) & (K Units)
Table 20. Global Anti-VEGT Drugs Sales Market Share by Region (2026-2031)
Table 21. Global Anti-VEGT Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Anti-VEGT Drugs Revenue Market Share by Region (2020-2025)
Table 23. Global Anti-VEGT Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Anti-VEGT Drugs Revenue Market Share by Region (2026-2031)
Table 25. North America Anti-VEGT Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Anti-VEGT Drugs Sales by Country (2020-2025) & (K Units)
Table 27. North America Anti-VEGT Drugs Sales by Country (2026-2031) & (K Units)
Table 28. North America Anti-VEGT Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Anti-VEGT Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Anti-VEGT Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Anti-VEGT Drugs Sales by Country (2020-2025) & (K Units)
Table 32. Europe Anti-VEGT Drugs Sales by Country (2026-2031) & (K Units)
Table 33. Europe Anti-VEGT Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Anti-VEGT Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Anti-VEGT Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Anti-VEGT Drugs Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Anti-VEGT Drugs Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Anti-VEGT Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Anti-VEGT Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Anti-VEGT Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Anti-VEGT Drugs Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Anti-VEGT Drugs Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Anti-VEGT Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Anti-VEGT Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Anti-VEGT Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Anti-VEGT Drugs Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Anti-VEGT Drugs Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Anti-VEGT Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Anti-VEGT Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Anti-VEGT Drugs Sales (K Units) by Type (2020-2025)
Table 51. Global Anti-VEGT Drugs Sales (K Units) by Type (2026-2031)
Table 52. Global Anti-VEGT Drugs Sales Market Share by Type (2020-2025)
Table 53. Global Anti-VEGT Drugs Sales Market Share by Type (2026-2031)
Table 54. Global Anti-VEGT Drugs Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Anti-VEGT Drugs Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Anti-VEGT Drugs Revenue Market Share by Type (2020-2025)
Table 57. Global Anti-VEGT Drugs Revenue Market Share by Type (2026-2031)
Table 58. Global Anti-VEGT Drugs Price (US$/Unit) by Type (2020-2025)
Table 59. Global Anti-VEGT Drugs Price (US$/Unit) by Type (2026-2031)
Table 60. Global Anti-VEGT Drugs Sales (K Units) by Application (2020-2025)
Table 61. Global Anti-VEGT Drugs Sales (K Units) by Application (2026-2031)
Table 62. Global Anti-VEGT Drugs Sales Market Share by Application (2020-2025)
Table 63. Global Anti-VEGT Drugs Sales Market Share by Application (2026-2031)
Table 64. Global Anti-VEGT Drugs Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Anti-VEGT Drugs Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Anti-VEGT Drugs Revenue Market Share by Application (2020-2025)
Table 67. Global Anti-VEGT Drugs Revenue Market Share by Application (2026-2031)
Table 68. Global Anti-VEGT Drugs Price (US$/Unit) by Application (2020-2025)
Table 69. Global Anti-VEGT Drugs Price (US$/Unit) by Application (2026-2031)
Table 70. Genentech (Roche) Company Information
Table 71. Genentech (Roche) Description and Business Overview
Table 72. Genentech (Roche) Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Genentech (Roche) Anti-VEGT Drugs Product
Table 74. Genentech (Roche) Recent Developments/Updates
Table 75. Regeneron Pharmaceuticals Company Information
Table 76. Regeneron Pharmaceuticals Description and Business Overview
Table 77. Regeneron Pharmaceuticals Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Regeneron Pharmaceuticals Anti-VEGT Drugs Product
Table 79. Regeneron Pharmaceuticals Recent Developments/Updates
Table 80. Novartis Company Information
Table 81. Novartis Description and Business Overview
Table 82. Novartis Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Novartis Anti-VEGT Drugs Product
Table 84. Novartis Recent Developments/Updates
Table 85. AstraZeneca Company Information
Table 86. AstraZeneca Description and Business Overview
Table 87. AstraZeneca Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. AstraZeneca Anti-VEGT Drugs Product
Table 89. AstraZeneca Recent Developments/Updates
Table 90. Bayer Company Information
Table 91. Bayer Description and Business Overview
Table 92. Bayer Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Bayer Anti-VEGT Drugs Product
Table 94. Bayer Recent Developments/Updates
Table 95. Abbott Company Information
Table 96. Abbott Description and Business Overview
Table 97. Abbott Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Abbott Anti-VEGT Drugs Product
Table 99. Abbott Recent Developments/Updates
Table 100. Santen Company Information
Table 101. Santen Description and Business Overview
Table 102. Santen Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Santen Anti-VEGT Drugs Product
Table 104. Santen Recent Developments/Updates
Table 105. Pfizer Company Information
Table 106. Pfizer Description and Business Overview
Table 107. Pfizer Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Pfizer Anti-VEGT Drugs Product
Table 109. Pfizer Recent Developments/Updates
Table 110. Sanofi Company Information
Table 111. Sanofi Description and Business Overview
Table 112. Sanofi Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Sanofi Anti-VEGT Drugs Product
Table 114. Sanofi Recent Developments/Updates
Table 115. Bristol-Myers Squibb Company Information
Table 116. Bristol-Myers Squibb Description and Business Overview
Table 117. Bristol-Myers Squibb Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Bristol-Myers Squibb Anti-VEGT Drugs Product
Table 119. Bristol-Myers Squibb Recent Developments/Updates
Table 120. GlaxoSmithKline Company Information
Table 121. GlaxoSmithKline Description and Business Overview
Table 122. GlaxoSmithKline Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. GlaxoSmithKline Anti-VEGT Drugs Product
Table 124. GlaxoSmithKline Recent Developments/Updates
Table 125. Eli Lilly & Company Company Information
Table 126. Eli Lilly & Company Description and Business Overview
Table 127. Eli Lilly & Company Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Eli Lilly & Company Anti-VEGT Drugs Product
Table 129. Eli Lilly & Company Recent Developments/Updates
Table 130. Chugai Pharma Company Information
Table 131. Chugai Pharma Description and Business Overview
Table 132. Chugai Pharma Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. Chugai Pharma Anti-VEGT Drugs Product
Table 134. Chugai Pharma Recent Developments/Updates
Table 135. Kanghong Pharmaceutical Company Information
Table 136. Kanghong Pharmaceutical Description and Business Overview
Table 137. Kanghong Pharmaceutical Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Kanghong Pharmaceutical Anti-VEGT Drugs Product
Table 139. Kanghong Pharmaceutical Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Anti-VEGT Drugs Distributors List
Table 143. Anti-VEGT Drugs Customers List
Table 144. Anti-VEGT Drugs Market Trends
Table 145. Anti-VEGT Drugs Market Drivers
Table 146. Anti-VEGT Drugs Market Challenges
Table 147. Anti-VEGT Drugs Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
Table 151. Authors List of This Report
List of Figures
Figure 1. Product Picture of Anti-VEGT Drugs
Figure 2. Global Anti-VEGT Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Anti-VEGT Drugs Market Share by Type: 2024 & 2031
Figure 4. Tyrosine Kinase Inhibitors Product Picture
Figure 5. Monoclonal Antibodies Product Picture
Figure 6. Others Product Picture
Figure 7. Global Anti-VEGT Drugs Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Anti-VEGT Drugs Market Share by Application: 2024 & 2031
Figure 9. Oncology
Figure 10. Ophthalmology
Figure 11. Others
Figure 12. Global Anti-VEGT Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Anti-VEGT Drugs Market Size (2020-2031) & (US$ Million)
Figure 14. Global Anti-VEGT Drugs Sales (2020-2031) & (K Units)
Figure 15. Global Anti-VEGT Drugs Average Price (US$/Unit) & (2020-2031)
Figure 16. Anti-VEGT Drugs Report Years Considered
Figure 17. Anti-VEGT Drugs Sales Share by Manufacturers in 2024
Figure 18. Global Anti-VEGT Drugs Revenue Share by Manufacturers in 2024
Figure 19. Global 5 and 10 Largest Anti-VEGT Drugs Players: Market Share by Revenue in Anti-VEGT Drugs in 2024
Figure 20. Anti-VEGT Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Global Anti-VEGT Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 22. North America Anti-VEGT Drugs Sales Market Share by Country (2020-2031)
Figure 23. North America Anti-VEGT Drugs Revenue Market Share by Country (2020-2031)
Figure 24. United States Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Canada Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Europe Anti-VEGT Drugs Sales Market Share by Country (2020-2031)
Figure 27. Europe Anti-VEGT Drugs Revenue Market Share by Country (2020-2031)
Figure 28. Germany Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. France Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. U.K. Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Italy Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Russia Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Asia Pacific Anti-VEGT Drugs Sales Market Share by Region (2020-2031)
Figure 34. Asia Pacific Anti-VEGT Drugs Revenue Market Share by Region (2020-2031)
Figure 35. China Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Japan Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. South Korea Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. India Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Australia Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. China Taiwan Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Southeast Asia Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Latin America Anti-VEGT Drugs Sales Market Share by Country (2020-2031)
Figure 43. Latin America Anti-VEGT Drugs Revenue Market Share by Country (2020-2031)
Figure 44. Mexico Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Brazil Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Argentina Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Middle East and Africa Anti-VEGT Drugs Sales Market Share by Country (2020-2031)
Figure 48. Middle East and Africa Anti-VEGT Drugs Revenue Market Share by Country (2020-2031)
Figure 49. Turkey Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Saudi Arabia Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. UAE Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Global Sales Market Share of Anti-VEGT Drugs by Type (2020-2031)
Figure 53. Global Revenue Market Share of Anti-VEGT Drugs by Type (2020-2031)
Figure 54. Global Anti-VEGT Drugs Price (US$/Unit) by Type (2020-2031)
Figure 55. Global Sales Market Share of Anti-VEGT Drugs by Application (2020-2031)
Figure 56. Global Revenue Market Share of Anti-VEGT Drugs by Application (2020-2031)
Figure 57. Global Anti-VEGT Drugs Price (US$/Unit) by Application (2020-2031)
Figure 58. Anti-VEGT Drugs Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232